Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A

Haemophilia

Volumn 16, Issue 6, 2010, Pages 892-901

  Van Helden, P M W ^a   Kaijen, P H P ^a   Mauser Bunschoten, E P ^b   Fischer, K ^b,c   Van Den Berg, H M ^b,c   Voorberg, Jan ^a  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Epitope mapping; Factor VIII; Factor VIII inhibitors; Haemophilia; Immune tolerance

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CRYOPRECIPITATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; INTERMEDIATE PURITY PLASMA DERIVED BLOOD CLOTTING FACTOR 8; MONOCLONALLY PURIFIED PLASMA DERIVED BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INFANT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DOMAIN; SCHOOL CHILD;

ANTIBODY SPECIFICITY; BLOOD COAGULATION FACTOR INHIBITORS; COHORT STUDIES; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; MUTATION;

EID: 78049307973     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02272.x     Document Type: Article

References (37)

1. Mannucci PM, Tuddenham EG. The haemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Gouw SC, Van Den Berg HM, Le Cessie S, Van Der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe haemophilia A. J Thromb Haemost 2007; 5: 1383-90.
3. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2004; 2: 1082-95.
4. Saenko EL, Ananyeva NM, Kouiavskaia DV et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia 2002; 8: 1-11.
5. Toole JJ, Knopf JL, Wozney JM et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-7.
6. Ananyeva NM, Lacroix-Desmazes S, Hauser CA et al. Inhibitors in haemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 2004; 15: 109-24.
7. Healey JF, Barrow RT, Tamim HM et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92: 3701-9.
8. Scandella D, Gilbert GE, Shima M et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-9.
9. Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JM, Lollar P. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood 2001; 97: 169-74.
10. Spiegel PC Jr, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001; 98: 13-9.
11. Gilbert GE, Kaufman RJ, Arena AA, Miao H, Pipe SW. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 277: 6374-81.
12. Van Den Brink EN, Bril WS, Turenhout EA et al. Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. Blood 2002; 99: 2828-34.
13. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Antihuman factor VIII C2 domain antibodies in haemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-42.
14. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood 2008; 112: 1151-3.
15. Healey JF, Lubin IM, Nakai H et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505-9.
16. Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274: 29826-30.
17. Lollar P, Parker ET, Curtis JE et al. Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J Clin Invest 1994; 93: 2497-504.
18. Fijnvandraat K, Celie PH, Turenhout EA et al. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood 1998; 91: 2347-52.
19. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92: 136-42.
20. Prescott R, Nakai H, Saenko EL et al. The inhibitor antibody response is more complex in haemophilia A patients than in most nonhaemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 3663-71.
21. Fulcher CA, Lechner K, De Graaf MS. Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 1988; 72: 1348-56.
22. Dimichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009; 15: 320-8.
23. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in haemophilia A: a review. Semin Thromb Hemost 2003; 29: 69-76.
24. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, Van Den Berg HM. Low-dose immune tolerance induction in haemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
25. Van Helden PM, Van Den Berg HM, Gouw SC et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with haemophilia A. Br J Haematol 2008; 142: 644-52.
26. Fijnvandraat K, Turenhout EA, Van Den Brink EN et al. The missense mutation Arg593 --> Cys is related to antibody formation in a patient with mild haemophilia A. Blood 1997; 89: 4371-7.
27. Lenting PJ, Donath MJ, Van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 1994; 269: 7150-5.
28. Van Den Brink EN, Timmermans SM, Turenhout EA et al. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution. Thromb Haemost 1999; 81: 723-6.
29. Kasper CK, Aledort L, Aronson D et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
30. Verbruggen B, Novakova I, Wessels H, Boezeman J, Van Den BM, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
31. Moreau A, Lacroix-Desmazes S, Stieltjes N et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe haemophilia A and in normal polyclonal human IgG. Blood 2000; 95: 3435-41.
32. Ware J, Toomey JR, Stafford DW. Localization of a factor VIII-inhibiting antibody epitope to a region between residues 338 and 362 of factor VIII heavy chain. Proc Natl Acad Sci U S A 1988; 85: 3165-9.
33. Huang CC, Shen MC, Chen JY, Hung MH, Hsu TC, Lin SW. Epitope mapping of factor VIII inhibitor antibodies of Chinese origin. Br J Haematol 2001; 113: 915-24.
34. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. J Thromb Haemost 2009; 7: 658-64.
35. Kreuz W. The role of VWF for the success of immune tolerance induction. Thromb Res 2008; 122(Suppl. 2): S7-12.
36. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008; 14: 295-302.
37. DiMichele DM, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271-3.